Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
2001 1
2003 4
2004 1
2005 1
2006 1
2008 1
2009 2
2010 1
2011 4
2013 3
2014 5
2015 13
2016 15
2017 10
2018 27
2019 21
2020 25
2021 19
2022 21
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 31586002

154 results
Results by year
Filters applied: . Clear all
Page 1
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting.
Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O'Donoghue JA, Ziolkowska M, Ruan S, Lyashchenko SK, Tsai F, Farwell M, Mitchell TC, Korn R, Le W, Lewis JS, Weber WA, Behera D, Wilson I, Gordon M, Wu AM, Wolchok JD. Pandit-Taskar N, et al. J Nucl Med. 2020 Apr;61(4):512-519. doi: 10.2967/jnumed.119.229781. Epub 2019 Oct 4. J Nucl Med. 2020. PMID: 31586002 Free PMC article. Clinical Trial.
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody.
Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, Mascioni A, Le W, Wilson I, Gordon MS, Wu AM, Ulaner GA, Wolchok JD, Postow MA, Pandit-Taskar N. Farwell MD, et al. J Nucl Med. 2022 May;63(5):720-726. doi: 10.2967/jnumed.121.262485. Epub 2021 Aug 19. J Nucl Med. 2022. PMID: 34413145 Free PMC article. Clinical Trial.
Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy.
Maresca KP, Chen J, Mathur D, Giddabasappa A, Root A, Narula J, King L, Schaer D, Golas J, Kobylarz K, Rosfjord E, Keliher E, Chen L, Ram S, Pickering EH, Hardwick JS, Rejto PA, Hussein A, Ilovich O, Staton K, Wilson I, McCarthy TJ. Maresca KP, et al. Mol Imaging Biol. 2021 Dec;23(6):941-951. doi: 10.1007/s11307-021-01621-0. Epub 2021 Jun 18. Mol Imaging Biol. 2021. PMID: 34143379 Free PMC article.
The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment.
Griessinger CM, Olafsen T, Mascioni A, Jiang ZK, Zamilpa C, Jia F, Torgov M, Romero JM, Marchioni F, Satpayev D, Lee C, Zhang G, Nayak TK, Pincha M, Amann M, Mohan PLB, Richard M, Nicolini VG, Sam J, Claus C, Ferrara C, Brünker P, Bacac M, Umana P, Rüttinger D, Wilson IA, Gudas J, Klein C, Tessier JJL. Griessinger CM, et al. Cancer Res. 2020 Jul 1;80(13):2903-2913. doi: 10.1158/0008-5472.CAN-19-3269. Epub 2020 May 14. Cancer Res. 2020. PMID: 32409308
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE, Wu AM, Weber WA, Scher HI, Larson SM, Morris MJ. Pandit-Taskar N, et al. J Nucl Med. 2016 Dec;57(12):1858-1864. doi: 10.2967/jnumed.116.176206. Epub 2016 Aug 11. J Nucl Med. 2016. PMID: 27516450 Free PMC article. Clinical Trial.
PET/CT Imaging of 89Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys.
Li W, Wang Y, Rubins D, Bennacef I, Holahan M, Haley H, Purcell M, Gantert L, Hseih S, Judo M, Seghezzi W, Zhang S, van der Veen EL, Lub-de Hooge MN, de Vries EGE, Evelhoch JL, Klimas M, Hostetler ED. Li W, et al. Mol Imaging Biol. 2021 Apr;23(2):250-259. doi: 10.1007/s11307-020-01558-w. Epub 2020 Oct 26. Mol Imaging Biol. 2021. PMID: 33104972 Free PMC article.
Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.
O'Donoghue JA, Danila DC, Pandit-Taskar N, Beylergil V, Cheal SM, Fleming SE, Fox JJ, Ruan S, Zanzonico PB, Ragupathi G, Lyashchenko SK, Williams SP, Scher HI, Fine BM, Humm JL, Larson SM, Morris MJ, Carrasquillo JA. O'Donoghue JA, et al. Mol Pharm. 2019 Jul 1;16(7):3083-3090. doi: 10.1021/acs.molpharmaceut.9b00326. Epub 2019 May 31. Mol Pharm. 2019. PMID: 31117485 Free PMC article.
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.
Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming SE, Fox JJ, Cheal SM, O'Donoghue JA, Ruan S, Ragupathi G, Lyashchenko SK, Humm JL, Scher HI, Gönen M, Williams SP, Danila DC, Morris MJ. Carrasquillo JA, et al. J Nucl Med. 2019 Nov;60(11):1517-1523. doi: 10.2967/jnumed.118.222844. Epub 2019 May 3. J Nucl Med. 2019. PMID: 31053681 Free PMC article. Clinical Trial.
154 results